Fresenius SE & Co. KGaA (FSNUF) Stock

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.

Fresenius SE & Co. KGaA is headquartered in DE.

Fresenius SE & Co. KGaA (FSNUF) stock trades at $54.35 with a market capitalization of $30.61B. The stock is valued at a price-to-earnings (P/E) ratio of 15.70, price-to-book of 1.18, price-to-sales of 1.02. Over the past 52 weeks the stock has ranged between $46.21 and $58.16, and currently trades 6.6% below its 52-week high. It pays a dividend yielding 2.24%.

On profitability, Fresenius SE & Co. KGaA generates a return on equity (ROE) of 7.76%, return on capital employed of 6.63%, an operating margin of 9.45%, a net profit margin of 6.38%.

In its most recent fiscal year, Fresenius SE & Co. KGaA reported annual revenue of $22.9B, net profit of $1.3B, revenue has compounded at -8.8% a year over the last five years, profit at -14.8% a year.

The balance sheet shows a debt-to-equity ratio of 0.60, a current ratio of 1.27, total assets of $41.4B, $1.6B in cash and equivalents.

FSNUF has an average daily trading volume of 100.552 shares, a beta of 0.82.

Official website: www.fresenius.com